GSK has the option to negotiate an exclusive license to VBI’s LPV Platform for use in a defined field.
“With our partners, we seek to develop a next generation of vaccines and biologics with improved stability characteristics that allow for consistently safe and effective administration in both established and emerging markets,” said Jeff Baxter, president and chief executive officer, VBI. “We’re thrilled to be working with GlaxoSmithKline, a leading global healthcare company, to explore the potential of the LPV technology to their pipeline. This collaboration further validates the significant potential of our LPV Platform.”
Stability is a critical issue potentially affecting vaccine potency, safety and ultimately patient access. The LPV Platform uses a proprietary formulation and process to enclose and protect the antigen (active component) of a vaccine or biologic. VBI has completed proof of concept studies on a number of vaccine and biologic targets that demonstrate the LPV Platform’s ability to preserve potency under stress conditions.